Hasil Pencarian - Kenneth O’byrne

  • Menampilkan 1 - 15 hasil dari 15
Perbaiki Hasil
  1. 1
    PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance

    PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance oleh Maddison Rose, Joshua T. Burgess, Kenneth O’Byrne, Kenneth O’Byrne, Derek J. Richard, Emma Bolderson

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy

    Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy oleh Thais Sobanski, Maddison Rose, Amila Suraweera, Kenneth O’Byrne, Kenneth O’Byrne, Derek J. Richard, Emma Bolderson, Emma Bolderson

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

    The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer oleh Joanna Kapeleris, Joanna Kapeleris, Arutha Kulasinghe, Arutha Kulasinghe, Majid E. Warkiani, Majid E. Warkiani, Ian Vela, Ian Vela, Liz Kenny, Kenneth O'Byrne, Kenneth O'Byrne, Kenneth O'Byrne, Chamindie Punyadeera, Chamindie Punyadeera

    Diterbitkan 2018-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    43 Highly multiplexed digital spatial profiling of the tumor microenvironment of non-small-cell lung cancer (NSCLC)

    43 Highly multiplexed digital spatial profiling of the tumor microenvironment of non-small-cell lung cancer (NSCLC) oleh Arutha Kulasinghe, Connor O’Leary, Rahul Ladwa, Majid Warkiani, Kenneth O’byrne

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.

    Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. oleh Magdalena Circu, James Cardelli, Martin P Barr, Kenneth O'Byrne, Glenn Mills, Hazem El-Osta

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.

    Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung ca... oleh Magdalena Circu, James Cardelli, Martin P Barr, Kenneth O'Byrne, Glenn Mills, Hazem El-Osta

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

    Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update oleh Joanna Kapeleris, Joanna Kapeleris, Majid Ebrahimi Warkiani, Arutha Kulasinghe, Arutha Kulasinghe, Ian Vela, Ian Vela, Ian Vela, Liz Kenny, Rahul Ladwa, Rahul Ladwa, Kenneth O’Byrne, Kenneth O’Byrne, Chamindie Punyadeera, Chamindie Punyadeera, Chamindie Punyadeera

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report

    Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report oleh James Fletcher, MBBS, Robert Bird, MBBS, Andrew J.W. McLean, MBBS, Kenneth O’Byrne, MD, Wen Xu, MBBS

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Stochastic epithelial-mesenchymal transitions diversify non-cancerous lung cell behaviours

    Stochastic epithelial-mesenchymal transitions diversify non-cancerous lung cell behaviours oleh Sugandha Bhatia, Jennifer H Gunter, Joshua T Burgess, Mark N Adams, Kenneth O'Byrne, Erik W Thompson, Pascal HG Duijf

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Glycan Profiling in Small Extracellular Vesicles with a SERS Microfluidic Biosensor Identifies Early Malignant Development in Lung Cancer

    Glycan Profiling in Small Extracellular Vesicles with a SERS Microfluidic Biosensor Identifies Early Malignant Development in Lung Cancer oleh Quan Zhou, Xueming Niu, Zhen Zhang, Kenneth O'Byrne, Arutha Kulasinghe, David Fielding, Andreas Möller, Alain Wuethrich, Richard J. Lobb, Matt Trau

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer

    Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer oleh Joanna Kapeleris, Juliana Müller Bark, Shanon Ranjit, Darryl Irwin, Gunter Hartel, Majid Ebrahimi Warkiani, Paul Leo, Connor O'Leary, Rahul Ladwa, Kenneth O'Byrne, Brett G.M. Hughes, Chamindie Punyadeera

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Protein Tyrosine Phosphatase Non-Receptor 11 (<i>PTPN11</i>/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

    Protein Tyrosine Phosphatase Non-Receptor 11 (<i>PTPN11</i>/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC) oleh Cathy E. Richards, Yasir Y. Elamin, Aoife Carr, Kathy Gately, Shereen Rafee, Mattia Cremona, Emer Hanrahan, Robert Smyth, Daniel Ryan, Ross K. Morgan, Susan Kennedy, Lance Hudson, Joanna Fay, Kenneth O’Byrne, Bryan T. Hennessy, Sinead Toomey

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

    A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE oleh Lavinia Tan, Chris Brown, Antony Mersiades, Chee Khoon Lee, Thomas John, Steven Kao, Genni Newnham, Kenneth O’Byrne, Sagun Parakh, Victoria Bray, Kevin Jasas, Sonia Yip, Stephen Q. Wong, Sarah Ftouni, Jerick Guinto, Sushma Chandrashekar, Stephen Clarke, Nick Pavlakis, Martin R. Stockler, Sarah-Jane Dawson, Benjamin J. Solomon

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

    Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples oleh Sinead Toomey, Aoife Carr, Mateusz Janusz Mezynski, Yasir Elamin, Shereen Rafee, Mattia Cremona, Clare Morgan, Stephen Madden, Khairun I. Abdul-Jalil, Kathy Gately, Angela Farrelly, Elaine W. Kay, Susan Kennedy, Kenneth O’Byrne, Liam Grogan, Oscar Breathnach, Patrick G. Morris, Alexander J. Eustace, Joanna Fay, Robert Cummins, Anthony O’Grady, Roshni Kalachand, Norma O’Donovan, Fergal Kelleher, Aine O’Reilly, Mark Doherty, John Crown, Bryan T. Hennessy

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

    ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance oleh Malinda Itchins, BMedSci, M.B.B.S., FRACP, PhD, Shirley Liang, BSc, Chris Brown, MBiostats, BSc, Tristan Barnes, BSc (Med), M.B.B.S., FRACP, Gavin Marx, BSc, M.B.B.S., FRACP, Venessa Chin, M.B.B.S., FRACP, PhD, Steven Kao, BHB, MBChB, PhD, FRACP, Po Yee Yip, MBChB, FRACP, PhD, Antony J. Mersiades, BMedSc, M.B.B.S., FRACP, MMed (Clin. Epi), Adnan Nagrial, M.B.B.S., FRACP, PhD, Victoria Bray, M.B.B.S., FRACP, PhD, Geoffrey Peters, BPharm, M.B.B.S., FRACP, Sagun Parakh, BSc, MBChB, FRACP, PhD, Kavita Garg, PhD, Bob T. Li, MD, PhD, MPH, Matthew McKay, PhD, Kenneth O'Byrne, M.B.B.S., FRACP, FRCPA, MD, Thomas John, M.B.B.S., FRACP, PhD, Anthony J. Gill, MD, FRCPA, Mark P. Molloy, PhD, Benjamin J. Solomon, M.B.B.S., FRACP, PhD, Nick Pavlakis, BSc, M.B.B.S., MMed (Clin. Epi), PhD, FRACP

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: